Harrow launches next-generation compounded atropine formulations

Eyecare professionals can order these new compounded atropine formulations for as low as $39 per 5mL bottle. (Adobe Stock image)

Harrow today announced the launch of its patent-pending, next-generation compounded atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.

In a news release, Harrow CEO Mark L. Baum pointed out that the company’s mission has been to help eyecare professionals address the unmet needs of patients and make ophthalmic medications both accessible and affordable.

“The availability of these innovative compounded atropine formulations is in keeping with our mission,” Baum said in the release. “We believe ophthalmologists, optometrists, and the millions of Americans who may benefit from topical atropine therapy, will appreciate the tremendous value these patent-pending formulations offer.”

Key attributes of the ImprimisRX next-generation atropine formulations:

• Undergo validated analytical tests to ensure consistency, potency, and stability. 
• Do not contain either preservatives or boric acid.
• Have a physiologic pH of 5.5.
• May be stored at room temperature for up to 180 days.

According to the news release, eyecare professionals can order these new compounded atropine formulations for as low as $39 per 5mL bottle – either online at atropine.com or by calling or texting 615‑437‑4690 to speak to ImprimisRx Customer Service.

The company noted that compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. Compounded medications are not reviewed by the FDA for safety or efficacy. ImprimisRx does not compound copies of commercially available products.